학술논문

Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-kappa B subunit RelA
Document Type
Journal
Source
PROTEOMICS CLINICAL APPLICATIONS; NOV 17 2021, pe2100072 11p.
Subject
Language
English
ISSN
18628354